Project Grant HT94252510537
Award Date
7/1/25
Completion Date
6/30/28
Dollars Obligated
$969K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Tampa, FL 33612, USA
Similar Awards
The U.S. Department of Defense's Defense Health Agency awarded a $481,749 Project Grant to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. (Moffitt Cancer Center) under the Military Medical Research and Development program (CFDA 12.420). The grant, effective September 30, 2023 through September 29, 2026, will support research to dissect the spatial molecular architecture of the transformed cutaneous T cell lymphoma tumor microenvironment, with the goal of identifying novel...
The U.S. Defense Health Agency awarded a $1,619,065 project grant to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. under the Military Medical Research and Development program (CFDA 12.420). The grant, with a period of performance from April 15, 2025 to April 14, 2029, will fund the development of a behavioral intervention for young adults with advanced cancer. As a National Cancer Institute-designated comprehensive cancer center, the Moffitt Cancer Center specializes...
This $328,574 Project Grant award from the Defense Health Agency's Military Medical Research and Development (CFDA 12.420) program supports research by the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The grant funds a project to quantify the spatial properties of immunosuppressive macrophages in papillary renal cell carcinoma, with a performance period from July 1, 2025 to June 30, 2028. The project aims to advance understanding of cancer biology and...
This federal Project Grant award, valued at $168,500.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant supports research conducted by the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida, to cotarget Type 1 PRMTS and YAP1 in order to combat EGFR-mutant lung adenocarcinoma. The grant period runs from September 1, 2024 to August 31, 2025. The Moffitt Cancer Center is a nonprofit,...
The U.S. Department of Defense's Defense Health Agency has awarded a $762,168 Project Grant to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. under the Military Medical Research and Development (CFDA 12.420) program. The grant, with a project period from September 30, 2023 to September 29, 2026, is intended to "DECONVOLUTE KEY BIOLOGICAL DRIVERS THAT DEFINE SUBSETS OF LETHAL PROSTATE CANCER IN AFRICAN AMERICAN MEN." As a leading National Cancer...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $2,837,644 Project Grant to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The funding will support "Translational Studies for Targeted Alpha-Particle Therapy for Rare Melanomas" over a 4-year period from September 1, 2023 to August 31, 2027. This project grant aims to advance research into innovative cancer therapies, specifically exploring...
This $697,590 federal Project Grant award from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development program) supports research at the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. (Moffitt Cancer Center) to evaluate B-T cell cross-talk within tertiary lymphoid structures in melanoma progression and immune checkpoint blockade. The grant, with a performance period from July 1, 2024 to June 30, 2027, aims to advance scientific understanding of...
The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), has awarded a $328,575 Project Grant to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. This 3-year grant, with a start date of September 1, 2024, will support research aimed at "Reversing Exhaustion of Tumor-Infiltrating Lymphocytes for Improvement of Adoptive Cell Therapy." As a National Cancer Institute-designated comprehensive cancer...
The Defense Health Agency awarded H. Lee Moffitt Cancer Center And Research Institute Hospital, Inc. $842,500 under the Military Medical Research and Development federal grant program (CFDA 12.420) to define the glycoproteome in melanoma progression from June 1, 2023 to May 31, 2026. Through this award, Moffitt Cancer Center will investigate medical solutions for melanoma on the battlefield by defining the glycoproteome, which are glycosylated RNA and proteins, and how their expression changes...
This $844,231 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. (Moffitt Cancer Center) to target the POU2F3 protein in small cell lung cancer. The two-year grant, with a period of performance from July 1, 2024 to June 30, 2026, will enable Moffitt Cancer Center to conduct dual up- and downstream targeting of POU2F3, a...